Cogstate Limited
Cogstate Limited (CGS.AX) Stock Competitors & Peer Comparison
See (CGS.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CGS.AX | A$2.17 | -2.69% | 371M | 24.11 | A$0.09 | +0.92% |
| PME.AX | A$123.97 | +8.18% | 12.2B | 51.96 | A$2.25 | +0.53% |
| AYA.AX | A$3.31 | +7.82% | 372.1M | -19.24 | -A$0.17 | N/A |
| VHT.AX | A$1.15 | +0.44% | 291.3M | -28.63 | -A$0.04 | N/A |
| ONE.AX | A$0.18 | +2.86% | 141.9M | -6.17 | -A$0.03 | N/A |
| ALC.AX | A$0.10 | +3.09% | 131.6M | -9.80 | -A$0.01 | N/A |
| M7T.AX | A$0.33 | +20.00% | 77.6M | -8.25 | -A$0.04 | N/A |
| SHG.AX | A$0.22 | +4.76% | 75.8M | -12.00 | -A$0.02 | N/A |
| PHX.AX | A$0.11 | -4.55% | 72.5M | N/A | N/A | N/A |
| DOC.AX | A$0.13 | -7.14% | 51.3M | 14.00 | A$0.01 | N/A |
Stock Comparison
CGS.AX vs PME.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, PME.AX has a market cap of 12.2B. Regarding current trading prices, CGS.AX is priced at A$2.17, while PME.AX trades at A$123.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas PME.AX's P/E ratio is 51.96. In terms of profitability, CGS.AX's ROE is +0.27%, compared to PME.AX's ROE of +0.73%. Regarding short-term risk, CGS.AX is less volatile compared to PME.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check PME.AX's competition here
CGS.AX vs AYA.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, AYA.AX has a market cap of 372.1M. Regarding current trading prices, CGS.AX is priced at A$2.17, while AYA.AX trades at A$3.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas AYA.AX's P/E ratio is -19.24. In terms of profitability, CGS.AX's ROE is +0.27%, compared to AYA.AX's ROE of -0.36%. Regarding short-term risk, CGS.AX is less volatile compared to AYA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check AYA.AX's competition here
CGS.AX vs VHT.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, VHT.AX has a market cap of 291.3M. Regarding current trading prices, CGS.AX is priced at A$2.17, while VHT.AX trades at A$1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas VHT.AX's P/E ratio is -28.63. In terms of profitability, CGS.AX's ROE is +0.27%, compared to VHT.AX's ROE of -0.18%. Regarding short-term risk, CGS.AX is more volatile compared to VHT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check VHT.AX's competition here
CGS.AX vs ONE.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, ONE.AX has a market cap of 141.9M. Regarding current trading prices, CGS.AX is priced at A$2.17, while ONE.AX trades at A$0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas ONE.AX's P/E ratio is -6.17. In terms of profitability, CGS.AX's ROE is +0.27%, compared to ONE.AX's ROE of -2.27%. Regarding short-term risk, CGS.AX is more volatile compared to ONE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check ONE.AX's competition here
CGS.AX vs ALC.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, ALC.AX has a market cap of 131.6M. Regarding current trading prices, CGS.AX is priced at A$2.17, while ALC.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas ALC.AX's P/E ratio is -9.80. In terms of profitability, CGS.AX's ROE is +0.27%, compared to ALC.AX's ROE of +0.04%. Regarding short-term risk, CGS.AX is more volatile compared to ALC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check ALC.AX's competition here
CGS.AX vs M7T.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, M7T.AX has a market cap of 77.6M. Regarding current trading prices, CGS.AX is priced at A$2.17, while M7T.AX trades at A$0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas M7T.AX's P/E ratio is -8.25. In terms of profitability, CGS.AX's ROE is +0.27%, compared to M7T.AX's ROE of -0.24%. Regarding short-term risk, CGS.AX is less volatile compared to M7T.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check M7T.AX's competition here
CGS.AX vs SHG.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, SHG.AX has a market cap of 75.8M. Regarding current trading prices, CGS.AX is priced at A$2.17, while SHG.AX trades at A$0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas SHG.AX's P/E ratio is -12.00. In terms of profitability, CGS.AX's ROE is +0.27%, compared to SHG.AX's ROE of -0.60%. Regarding short-term risk, CGS.AX is less volatile compared to SHG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check SHG.AX's competition here
CGS.AX vs PHX.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, PHX.AX has a market cap of 72.5M. Regarding current trading prices, CGS.AX is priced at A$2.17, while PHX.AX trades at A$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas PHX.AX's P/E ratio is N/A. In terms of profitability, CGS.AX's ROE is +0.27%, compared to PHX.AX's ROE of -0.02%. Regarding short-term risk, CGS.AX is less volatile compared to PHX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check PHX.AX's competition here
CGS.AX vs DOC.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, DOC.AX has a market cap of 51.3M. Regarding current trading prices, CGS.AX is priced at A$2.17, while DOC.AX trades at A$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas DOC.AX's P/E ratio is 14.00. In terms of profitability, CGS.AX's ROE is +0.27%, compared to DOC.AX's ROE of +2.51%. Regarding short-term risk, CGS.AX is less volatile compared to DOC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check DOC.AX's competition here
CGS.AX vs BMT.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, BMT.AX has a market cap of 43.6M. Regarding current trading prices, CGS.AX is priced at A$2.17, while BMT.AX trades at A$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas BMT.AX's P/E ratio is -7.50. In terms of profitability, CGS.AX's ROE is +0.27%, compared to BMT.AX's ROE of -0.14%. Regarding short-term risk, CGS.AX is less volatile compared to BMT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check BMT.AX's competition here
CGS.AX vs VHL.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, VHL.AX has a market cap of 38.8M. Regarding current trading prices, CGS.AX is priced at A$2.17, while VHL.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas VHL.AX's P/E ratio is -2.00. In terms of profitability, CGS.AX's ROE is +0.27%, compared to VHL.AX's ROE of -4.12%. Regarding short-term risk, CGS.AX is less volatile compared to VHL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check VHL.AX's competition here
CGS.AX vs PCK.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, PCK.AX has a market cap of 33.4M. Regarding current trading prices, CGS.AX is priced at A$2.17, while PCK.AX trades at A$0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas PCK.AX's P/E ratio is -3.20. In terms of profitability, CGS.AX's ROE is +0.27%, compared to PCK.AX's ROE of -10.10%. Regarding short-term risk, CGS.AX is less volatile compared to PCK.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check PCK.AX's competition here
CGS.AX vs EMD.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, EMD.AX has a market cap of 28.6M. Regarding current trading prices, CGS.AX is priced at A$2.17, while EMD.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas EMD.AX's P/E ratio is -5.00. In terms of profitability, CGS.AX's ROE is +0.27%, compared to EMD.AX's ROE of -0.52%. Regarding short-term risk, CGS.AX is more volatile compared to EMD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check EMD.AX's competition here
CGS.AX vs COO.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, COO.AX has a market cap of 26.3M. Regarding current trading prices, CGS.AX is priced at A$2.17, while COO.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas COO.AX's P/E ratio is N/A. In terms of profitability, CGS.AX's ROE is +0.27%, compared to COO.AX's ROE of -0.05%. Regarding short-term risk, CGS.AX is more volatile compared to COO.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check COO.AX's competition here
CGS.AX vs IME.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, IME.AX has a market cap of 21.6M. Regarding current trading prices, CGS.AX is priced at A$2.17, while IME.AX trades at A$0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas IME.AX's P/E ratio is -6.67. In terms of profitability, CGS.AX's ROE is +0.27%, compared to IME.AX's ROE of -0.19%. Regarding short-term risk, CGS.AX is more volatile compared to IME.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check IME.AX's competition here
CGS.AX vs TRI.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, TRI.AX has a market cap of 20.8M. Regarding current trading prices, CGS.AX is priced at A$2.17, while TRI.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas TRI.AX's P/E ratio is N/A. In terms of profitability, CGS.AX's ROE is +0.27%, compared to TRI.AX's ROE of -0.08%. Regarding short-term risk, CGS.AX is less volatile compared to TRI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check TRI.AX's competition here
CGS.AX vs RHT.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, RHT.AX has a market cap of 19.6M. Regarding current trading prices, CGS.AX is priced at A$2.17, while RHT.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas RHT.AX's P/E ratio is N/A. In terms of profitability, CGS.AX's ROE is +0.27%, compared to RHT.AX's ROE of +0.08%. Regarding short-term risk, CGS.AX is more volatile compared to RHT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check RHT.AX's competition here
CGS.AX vs 1ST.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, 1ST.AX has a market cap of 15.6M. Regarding current trading prices, CGS.AX is priced at A$2.17, while 1ST.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas 1ST.AX's P/E ratio is -1.10. In terms of profitability, CGS.AX's ROE is +0.27%, compared to 1ST.AX's ROE of +0.69%. Regarding short-term risk, CGS.AX is more volatile compared to 1ST.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check 1ST.AX's competition here
CGS.AX vs MDR.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, MDR.AX has a market cap of 14M. Regarding current trading prices, CGS.AX is priced at A$2.17, while MDR.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas MDR.AX's P/E ratio is -0.20. In terms of profitability, CGS.AX's ROE is +0.27%, compared to MDR.AX's ROE of -2.31%. Regarding short-term risk, CGS.AX is less volatile compared to MDR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check MDR.AX's competition here
CGS.AX vs AHE.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, AHE.AX has a market cap of 12.1M. Regarding current trading prices, CGS.AX is priced at A$2.17, while AHE.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas AHE.AX's P/E ratio is -0.19. In terms of profitability, CGS.AX's ROE is +0.27%, compared to AHE.AX's ROE of -1.37%. Regarding short-term risk, CGS.AX is more volatile compared to AHE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check AHE.AX's competition here
CGS.AX vs ICR.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, ICR.AX has a market cap of 9.5M. Regarding current trading prices, CGS.AX is priced at A$2.17, while ICR.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas ICR.AX's P/E ratio is -2.00. In terms of profitability, CGS.AX's ROE is +0.27%, compared to ICR.AX's ROE of +5.38%. Regarding short-term risk, CGS.AX is less volatile compared to ICR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check ICR.AX's competition here
CGS.AX vs PKY.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, PKY.AX has a market cap of 8.5M. Regarding current trading prices, CGS.AX is priced at A$2.17, while PKY.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas PKY.AX's P/E ratio is -2.40. In terms of profitability, CGS.AX's ROE is +0.27%, compared to PKY.AX's ROE of -11.22%. Regarding short-term risk, CGS.AX is less volatile compared to PKY.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check PKY.AX's competition here
CGS.AX vs HIQ.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, HIQ.AX has a market cap of 6.9M. Regarding current trading prices, CGS.AX is priced at A$2.17, while HIQ.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas HIQ.AX's P/E ratio is -1.40. In terms of profitability, CGS.AX's ROE is +0.27%, compared to HIQ.AX's ROE of +1.53%. Regarding short-term risk, CGS.AX is less volatile compared to HIQ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check HIQ.AX's competition here
CGS.AX vs VFX.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, VFX.AX has a market cap of 6.8M. Regarding current trading prices, CGS.AX is priced at A$2.17, while VFX.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas VFX.AX's P/E ratio is -3.90. In terms of profitability, CGS.AX's ROE is +0.27%, compared to VFX.AX's ROE of +2.45%. Regarding short-term risk, CGS.AX is more volatile compared to VFX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check VFX.AX's competition here
CGS.AX vs ENL.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, ENL.AX has a market cap of 5.8M. Regarding current trading prices, CGS.AX is priced at A$2.17, while ENL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas ENL.AX's P/E ratio is -0.23. In terms of profitability, CGS.AX's ROE is +0.27%, compared to ENL.AX's ROE of -1.39%. Regarding short-term risk, CGS.AX is less volatile compared to ENL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check ENL.AX's competition here
CGS.AX vs OPL.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, OPL.AX has a market cap of 5.4M. Regarding current trading prices, CGS.AX is priced at A$2.17, while OPL.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas OPL.AX's P/E ratio is -2.20. In terms of profitability, CGS.AX's ROE is +0.27%, compared to OPL.AX's ROE of +12.68%. Regarding short-term risk, CGS.AX is more volatile compared to OPL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check OPL.AX's competition here
CGS.AX vs MEB.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, MEB.AX has a market cap of 4.5M. Regarding current trading prices, CGS.AX is priced at A$2.17, while MEB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas MEB.AX's P/E ratio is -0.10. In terms of profitability, CGS.AX's ROE is +0.27%, compared to MEB.AX's ROE of -0.15%. Regarding short-term risk, CGS.AX is less volatile compared to MEB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check MEB.AX's competition here
CGS.AX vs GLH.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, GLH.AX has a market cap of 3.9M. Regarding current trading prices, CGS.AX is priced at A$2.17, while GLH.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas GLH.AX's P/E ratio is -6.70. In terms of profitability, CGS.AX's ROE is +0.27%, compared to GLH.AX's ROE of +0.20%. Regarding short-term risk, CGS.AX is more volatile compared to GLH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check GLH.AX's competition here
CGS.AX vs TD1.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, TD1.AX has a market cap of 1.9M. Regarding current trading prices, CGS.AX is priced at A$2.17, while TD1.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas TD1.AX's P/E ratio is -2.05. In terms of profitability, CGS.AX's ROE is +0.27%, compared to TD1.AX's ROE of -0.42%. Regarding short-term risk, CGS.AX is more volatile compared to TD1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check TD1.AX's competition here
CGS.AX vs CTQ.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, CTQ.AX has a market cap of 1.7M. Regarding current trading prices, CGS.AX is priced at A$2.17, while CTQ.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas CTQ.AX's P/E ratio is -0.70. In terms of profitability, CGS.AX's ROE is +0.27%, compared to CTQ.AX's ROE of -0.14%. Regarding short-term risk, CGS.AX is more volatile compared to CTQ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check CTQ.AX's competition here
CGS.AX vs OAK.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, OAK.AX has a market cap of 1.7M. Regarding current trading prices, CGS.AX is priced at A$2.17, while OAK.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas OAK.AX's P/E ratio is 6.30. In terms of profitability, CGS.AX's ROE is +0.27%, compared to OAK.AX's ROE of +0.17%. Regarding short-term risk, CGS.AX is less volatile compared to OAK.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CGS.AX.Check OAK.AX's competition here
CGS.AX vs JTL.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, JTL.AX has a market cap of 281.3K. Regarding current trading prices, CGS.AX is priced at A$2.17, while JTL.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas JTL.AX's P/E ratio is -0.10. In terms of profitability, CGS.AX's ROE is +0.27%, compared to JTL.AX's ROE of +0.60%. Regarding short-term risk, CGS.AX is more volatile compared to JTL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check JTL.AX's competition here
CGS.AX vs TTB.AX Comparison April 2026
CGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 371M. In comparison, TTB.AX has a market cap of 267.4K. Regarding current trading prices, CGS.AX is priced at A$2.17, while TTB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 24.11, whereas TTB.AX's P/E ratio is -0.02. In terms of profitability, CGS.AX's ROE is +0.27%, compared to TTB.AX's ROE of -1.05%. Regarding short-term risk, CGS.AX is more volatile compared to TTB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CGS.AX.Check TTB.AX's competition here